The U.S. Food and Drug Administration (FDA) has recently approved Takeda’s HyQvia [immune globulin infusion 10% (human) with recombinant human hyaluronidase] as a maintenance therapy for adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP). This marks a significant advancement in the treatment of this debilitating neuromuscular disorder. HyQvia, unique for being the only subcutaneous immune globulin infusion administered monthly, was initially approved in 2014 for primary immunodeficiency in adults.
Giles Platford, president of the Takeda Plasma-Derived Therapies Business Unit, expressed enthusiasm about the FDA’s approval, noting that it expands Takeda’s expertise in rare neuroimmunological and neuromuscular disorders. This approval allows Takeda to offer a personalized maintenance treatment option for adults with chronic inflammatory demyelinating polyneuropathy, a disease that can severely impact quality of life. Platford emphasizes Takeda’s commitment to delivering a broad and diverse immunoglobulin (IG) portfolio to people with complex neuroimmunological diseases worldwide.
Subcutaneous Treatment for Enhanced Immunoglobulin Absorption and Broad-Spectrum Antibody Protection
HyQvia is an innovative liquid medication-infused under the skin into fatty subcutaneous tissue. It contains immunoglobulins derived from human plasma, essential for maintaining the body’s immune system. The drug’s therapeutic effect stems from its immune globulin infusion. HyQvia’s recombinant human hyaluronidase component enhances the dispersion and absorption of immunoglobulins in the body. It provides a wide range of opsonizing and neutralizing IgG antibodies, effective against various bacterial and viral agents.
The FDA’s approval is grounded in data from the ADVANCE-CIDP 1 trial, a randomized, double-blind, placebo-controlled study, and the ADVANCE-CIDP 3 trial, a single-arm, open-label, extension study. These studies enrolled 122 patients with confirmed chronic inflammatory demyelinating polyneuropathy diagnoses who had been on a stable intravenous immunoglobulin (IVIG) treatment regimen for at least three months before screening. Patients were assigned to receive either HyQvia or a placebo, matching their IVIG regimen frequency, for six months or until withdrawal or relapse. Those who did not experience a relapse had the option to continue treatment with HyQvia in the ADVANCE-CIDP 3 study, which assessed the long-term safety, tolerability, and immunogenicity of the medication.
The results showed a significant difference in relapse rates between patients treated with HyQvia (14.0%) and those receiving placebo (32.3%). This indicated HyQvia’s superiority in preventing chronic inflammatory demyelinating polyneuropathy relapse. The treatment difference of -18.3% with a two-sided 95% confidence interval of -32.1% to -3.1% underscored this point. Safety assessments revealed that the most common adverse events in chronic inflammatory demyelinating polyneuropathy patients treated with HyQvia were local reactions, headaches, pyrexia, nausea, fatigue, erythema, pruritus, increased lipase, abdominal pain, back pain, and extremity pains. These findings are critical as they demonstrate the drug’s tolerability and safety profile.
A Subcutaneous Alternative to Standard IVIG Therapy for Demyelinating Polyneuropathy Patients
Lisa Butler, the executive director of GBS-CIDP Foundation International, commented on the importance of this therapy. She noted that while intravenous immunoglobulin (IVIG) infusions are considered the standard of care for chronic inflammatory demyelinating polyneuropathy, they can be challenging for some patients and caregivers. The approval of HyQvia offers an alternative subcutaneous option, potentially addressing these challenges and allowing for more personalized treatment approaches.
In summary, the FDA’s approval of HyQvia for CIDP represents a pivotal moment in the treatment of this condition. It not only provides a new, effective maintenance therapy but also offers an alternative to the standard IVIG infusions. This approval is a testament to the ongoing efforts in medical research and pharmaceutical development to improve the lives of individuals living with complex and debilitating diseases like CIDP. The availability of HyQvia as a treatment option is expected to significantly enhance the quality of life for many patients, offering them a more manageable and effective way to combat their condition.
Resource: Pharmexec, January 18, 2024
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
